In addition, point mutations of the B-Raf proto-oncogene (BRAF) were observed in about 40% of PTCs and in a fraction equal to 20% of ATCs [4]. This evidence concerns the gene BRAF and Ehlers-Danlos syndrome, musculocontractural type.